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A B S T R A C T
Background
Standard treatment for high grade glioma (HGG) usually entails biopsy or surgical resection where possible followed by radiotherapy.
Systemic chemotherapy is usually only given in selected cases and its use is often limited by side effects. Implanting wafers impregnated
with chemotherapy agents into the resection cavity represents a novel means of delivering drugs to the central nervous system (CNS)
with fewer side effects. It is not clear how effective this modality is or whether it should be recommended as part of standard care for
HGG.
Objectives
To assess whether chemotherapeutic wafers have any advantage over conventional therapy for HGG.
Search strategy
The following databases were searched: The Cochrane Central Register of Controlled Trials (CENTRAL), Issue 2, 2007, MEDLINE,
EMBASE, SCIENCE CITATION INDEX, Physician Data Query and the meta-Register of Controlled Trials. Reference lists of all
identified studies were searched. The Journal of Neuro-Oncology was hand searched from 1999 to 2007, including all conference
abstracts. Neuro-oncologists were contacted regarding ongoing and unpublished trials.
Selection criteria
Patients included those of all ages with a presumed diagnosis of malignant glioma from clinical examination and radiology. Interventions
included insertion of chemotherapeutic wafers to the resection cavity at either primary surgery or for recurrent disease. Included studies
had to be randomised controlled trials (RCTs).
Data collection and analysis
Quality assessment and data extraction were undertaken by two review authors. Outcome measures included survival, time to progres-
sion, quality of life (QOL) and adverse events.
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Main results
In primary disease two RCTs assessing the effect of carmustine impregnated wafers (Gliadel®) and enrolling a total of 272 participants
were identified. Survival was increased (hazard ratio (HR) 0.65 confidence interval (CI) 0.48 to 0.86 p = 0.003). In recurrent disease a
single RCT was included assessing the effect of Gliadel® and enrolling 222 participants. It did not demonstrate a significant survival
increase (HR 0.83 CI 0.62 to 1.10 p = 0.2). There was no suitable data for time to progression or QOL. Adverse events were not more
common in either arm, and were presented in a descriptive fashion.
Authors’ conclusions
Gliadel® results in a prolongation of survival without an increased incidence of adverse events when used as primary therapy. There is
no evidence of enhanced progression free survival (PFS) or QOL. In recurrent disease, Gliadel® does not appear to confer any added
benefit. These findings are based on the results of three RCTs with approximately 500 patients in total.
P L A I N L A N G U A G E S U M M A R Y
High grade glioma is a rapidly progressive form of brain tumour: half of all patients will die within a year of diagnosis even
after treatment with surgery and radiotherapy
We found two trials, enrolling 272 people with newly diagnosed high grade glioma, which studied the effects of implanting wafers
coated with an anti-cancer drug called carmustine (Gliadel®) in the patients’ brains once the tumour was removed. This was compared
with implanting wafers that contained no drug. Both groups received radiotherapy afterwards. Patients who received carmustine wafers
had better survival and we found no evidence that carmustine led to a higher risk of side effects.
A similar trial enrolled 222 people who had already been diagnosed with high grade glioma and received surgery but had then had a
relapse of disease. In this situation the trial found that carmustine wafers did not prolong the lives of the patients.
B A C K G R O U N D
Gliomas are tumours of the brain and spinal cord, so called be-
cause they develop from the glial cells which form structures that
surround and support the nerve cells. Gliomas are graded by the
World Health Organisation classification on a scale of I to IV,
based on the histological appearance of the tumour (Kleihues
1993). HGGs belong to grades III or IV and have in common
an aggressive and infiltrating nature. The majority of HGGs are
Glioblastoma Multiforme (GBM), Anaplastic Astrocytoma (AA)
andAnaplasticOligodendrocytoma (AO). The incidence ofHGG
is less than 8 per 100,000 per year, resulting in around 4800 new
cases in the UK each year (Counsell 1996). Overall, HGG make
up about one percent of all new tumours types (SHS 2006).
In general, HGG have a poor prognosis. They are rapidly progres-
sive and resistant to therapy. Their infiltrating nature means they
cannot be completely excised and the majority will recur within
2cm of their original location. Median survival is around one year
for GBM, two years for AA and five years for AO (Winger 1989).
Management is based around symptomatic relief and improving
survival. The first option is surgery, which is usually required in
some form for histological diagnosis. It may be through a biopsy
or more aggressive attempted total resection. Currently there is
no good evidence from RCTs that either approach results in any
difference in survival over best medical care although resection is
commonly attempted where feasible (Hart 2000). Radiotherapy
is the treatment with most evidence for effectiveness and is now
part of standard management, resulting in an increase in median
survival from three to four months to around nine to ten months
(Walker 1978). The other principle therapy is oral glucocorticos-
teroids, which have an important role in the reduction of peri-tu-
moural oedema and can produce a marked improvement in neu-
rological symptoms and survival by themselves (Kaal 2004).
Many trials have been done using various different chemotherapy
regimes, the most common being a nitrosurea based regime of
Procarbazine, Lomustine and Vincristine (PCV). The results have
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generally been conflicting, although a meta-analysis has demon-
strated a statistically significant increase in survival with chemo-
therapy (HR 0.85 CI 0.78 to 0.92 p < 0.0001), which translates
into roughly a two month increase in median survival to around
12 months (GMT Group 2002). It is not clear whether the gain
in survival reflects a useful period of good QOL.
Recently the oral anti-cancer drug Temozolomide has been ap-
proved for use in selected cases of GBM in both the primary and
recurrent disease settings. A non-placebo controlled RCT found
temozolomide to be efficacious as part of first line therapy in pro-
longing survival and increasing time to progression in selected pa-
tients when given together with radiotherapy and for up to six
months after (Stupp 2005). Temozolomide is now becoming part
of the standard oncological repertoire for histologically confirmed
GBM in the primary disease setting in selected patients, although
side effects are including haematological toxicity are not in-fre-
quent and long term effects are unknown.
The most studied type of implantable chemotherapeutic wafer is
Gliadel®. This is a local therapy designed to be left on the tumour
bed at resection and provides a controlled release of 7.7mg car-
mustine over a period of two to three weeks. In theory this should
reduce systemic toxicities and allow a greater dose to be provided
to residual tumour than PCV chemotherapy (approximately 100
times greater). Wafer implantation at the time of surgery would
also simplify subsequent management, as systemic chemotherapy
is usually given over a prolonged course of around six months.
Early phase II series noted Gliadel® was a safe treatment for use
in GBM with associated good survival (Brem 1995; Kleinberg
2004). Despite these proposed advantages it is not clear whether
to recommend Gliadel® or any other chemotherapeutic wafer for
HGG as either primary therapy or for recurrent disease.
O B J E C T I V E S
To assess the effectiveness of implantable chemotherapeutic wafers
for HGG as part of;
• Initial therapy, or;
• Treatment of recurrent disease
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs.
Types of participants
Primary therapy: patients of all ages with a presumed diagnosis of
HGG on imaging.
Types of interventions
Intervention
• Surgery + chemotherapeutic wafer + radiotherapy
Comparison
• Surgery +/- placebo wafers + radiotherapy +/- systemic
chemotherapy e.g. PCV or temozolomide
We included trials which used other forms of supportive care e.g.
steroids, anti-epileptic drugs and other drugs as appropriate (Grant
2004) only if similar care was given to both the intervention and
comparison group.
Types of outcome measures
Primary outcomes
• Survival: from time of randomisation to death or censoring
Secondary outcomes
• Time to progression (TTP): from time of randomisation to
disease recurrence or censoring. Recurrence defined by both
clinical and radiological criteria (MacDonald 1990). This is
assumed to be roughly synonymous with PFS.
• QOL: as measured by a validated questionnaire.
• Adverse events; nature (as defined using MedDRA® -
Medical Dictionary for Regulatory Authorities) criteria and
timing. Procedure related mortality defined as within 30 days
post-intervention. Specific anticipated adverse events related to
the use of wafers include haemorrhage, infection and abscess
formation, peri-tumoural oedema, seizures and wound
complications.
Search methods for identification of studies
Electronic searches
The same principle was used to search each database. Firstly the
terms and phrases identifying randomised controlled trials were
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combined using the Boolean “OR”. Secondly, all the terms and
phrases describing malignant glioma, were combined with “OR”.
Thirdly, everything used to identify the interventions of interest
was combined with “OR”. These three initial search results were
then grouped with the Boolean operator “AND” and the results
displayed. Wild cards and truncation symbols were used to ensure
terms with alternative spellings and/or endings were not missed.
MeSH terms were exploded. The full search strategy is described
in Table 1: an example is given below for brevity. Foreign language
journals were eligible for inclusion.
Table 1. Full Search Strategy
Database Strategy
Medline MEDLINE (1966 to Jan Week 1 2007) Search Strategy.
Terms 1-37, used to identify all randomised and clinical controlled trials were taken
from the first two parts of the Highly Sensitive Search Strategy (HSSS) devised by
Carol Lefevre.
38. explode “Brain-Neoplasms”/all subheadings
39. explode “Central-Nervous-System-Neoplasms”/all subheadings
40. explode “Cerebral-Cortex”/all subheadings
41. explode “Glioma”/ all subheadings
42. malignant near glioma*
43. glioblastoma* or “glioblastoma multiforme”
44. astrocytoma* or “anaplastic astrocytoma”
45. oligodendrocytoma* or “anaplastic oligodendrocytoma”
46. brain tumo?r*
47. neuroectodermal tumo?r*
48. ependymoma*
49. oligodendroglioma*
50. or/38-49
51. explode “gliadel”
52. explode “carmustine wafers”
53. explode “absorbable implants”
54. explode “drug implants”
55. or/50-54
55. 37 and 50 and 55
Embase EMBASE (1980 to Jan 2007) Search Strategy.
The original search strategy has been adapted fromOvid version to SilverPlatter version,
all “MESH” headings were checked in Thesaurus (as the vocabulary was updated in
January 2003) and minor changes were made in “MESH” terms.
1.explode “clinical-trial”/all subheadings
2.explode “controlled-study”/all subheadings
3.explode “meta-analysis”/all subheadings
4.explode “crossover-procedure”/all subheadings
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Table 1. Full Search Strategy (Continued)
5.explode “double-blind-procedure”/all subheadings
6.explode “single-blind-procedure”/all subheadings
7.explode “randomization”/all subheadings
8.explode “prospective-study”/all subheadings
9.clin* near trial*
10.singl*
11.double*
12.(singl* or double* or trebl* or tripl*) near (blind* or mask*)
13.random*
14.control*
15.#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or
#14
16.EC = “HUMAN”
17.#15 and (EC = “HUMAN”)
18.explode “brain-tumor”/all subheadings
19.explode “central-nervous-system”/all subheadings
20.explode “brain-cortex”/all subheadings
21.malignant near glioma*
22.glioblastoma multiforme*
23.astrocytoma* or anaplastic astrocytoma*
24.brain tumo?r*
25.neuroectodermal tumo?r*
26.ependymoma*
27.oligodendroglioma*
28.#18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
29. explode“gliadel”
30. explode “carmustine wafers”
31. explode “absorbable implants”
32. explode “drug implants”
33. #29 or #30 or #31 or #32
33. 28 and 33
EMBASE (1980 to Jul 2006) Search Strategy.
The original search strategy has been adapted fromOvid version to SilverPlatter version,
all “MESH” headings were checked in Thesaurus (as the vocabulary was updated in
January 2003) and minor changes were made in “MESH” terms.
1.explode “clinical-trial”/all subheadings
2.explode “controlled-study”/all subheadings
3.explode “meta-analysis”/all subheadings
4.explode “crossover-procedure”/all subheadings
5.explode “double-blind-procedure”/all subheadings
6.explode “single-blind-procedure”/all subheadings
7.explode “randomization”/all subheadings
8.explode “prospective-study”/all subheadings
9.clin* near trial*
10.singl*
11.double*
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Table 1. Full Search Strategy (Continued)
12.(singl* or double* or trebl* or tripl*) near (blind* or mask*)
13.random*
14.control*
15.#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or
#14
16.EC = “HUMAN”
17.#15 and (EC = “HUMAN”)
18.explode “brain-tumor”/all subheadings
19.explode “central-nervous-system”/all subheadings
20.explode “brain-cortex”/all subheadings
21.malignant near glioma*
22.glioblastoma multiforme*
23.astrocytoma* or anaplastic astrocytoma*
24.brain tumo?r*
25.neuroectodermal tumo?r*
26.ependymoma*
27.oligodendroglioma*
28.#18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
29. explode“gliadel”
30. explode “carmustine wafers”
31. explode “absorbable implants”
32. explode “drug implants”
33. #29 or #30 or #31 or #32
33. 28 and 33
Science Citation Index SCIENCE CITATION INDEX (1981 to Jan 2007) Search Strategy
A similar search strategy to the one for Biosis was used. Searches were made in the
Title, Keyword or Abstract.
Unlike Biosis, there was no “major concepts” search facility.
The differences were as follows:
1. “tumo*” was used in place of “tumo*r”
2. “central & nervous & system & tumo*” and “central & nervous & system &
neoplasm” were two additional searches.
3. “extent & resection” was used in place of “extent of resection”
Cochrane Central Register of Controlled Trials (CENTRAL) on theCochrane Library,
Internet version, search strategy,
Capital letters areMESH terms, the rest are free text terms. The original search strategy
was used apart from the term:
18. ((biopsy near versus) near resection)- software did not allow to use this term
1.CENTRAL NERVOUS SYSTEM NEOPLASMS
2.BRAIN NEOPLASMS
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Table 1. Full Search Strategy (Continued)
3.GLIOMA
4.(malignant and glioma)
5.(glioblastoma and multiforme)
6.astrocytoma*
7.(anaplastic and astrocytoma*)
8.(brain and tumor*)
9.(neuroectodermal and tumor*)
10.(#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9)
11. (gliadel)
12. (carmustine wafers)
13. (absorbable implants)
14. (drug implants)
15. (#11 or #12 or #13)
16. 10 and 15
Physician Data Query Physician Data Query (PDQ): http://www.nci.nih.gov/cancertopics/pdq (Jan 2007)
Search form - all types of brain tumours - adults, children
Treatment
Active and closed
Phase III and IV
meta-Register of Controlled Trials (mRCT) meta-Register of Controlled Trials (mRCT): http://www.controlled-trials.com/mrct
(Jan 2007)
Keywords: brain, glioma, gliadel
The following databases were searched: The Cochrane Cen-
tral Register of Controlled Trials (CENTRAL), Issue 2, 2007.
MEDLINE, EMBASE, SCIENCE CITATION INDEX, Physi-
cian Data Query and the meta-Register of Controlled Trials.
Searching other resources
The references of all included studies were searched to identify
additional trials.
Hand search
A hand search of the Journal of Neuro-Oncology from 1991 to Jan
2007 was undertaken in order to identify trials that may not have
been present in the electronic databases. This included searching
all conference abstracts published in the journal.
Personal communication
The manufacturer of Gliadel® (Guilford Pharmaceuticals, now
owned byMGI Pharma) and its UK distributor (Link Pharmaceu-
ticals) was contacted regarding any further RCTs involving their
product. As they are the solemanufacturer of Gliadel® theywould
be aware of all research involving their product.
Data collection and analysis
Selection of studies
Identification of studies wasmade in two stages. Abstracts returned
by the original search were examined independently by two review
authors. Those studies that clearly did not meet the inclusion
criteria were excluded and copies of the full text of potentially
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relevant references were obtained. Next, full texts of the selected
references were obtained and further examined independently by
two authors for inclusion or exclusion criteria. At all times any
disagreements were resolved through discussion. If sufficient data
was not available for assessment then the relevant authors of the
trials were contacted.
Data extraction and management
For included studies, two review authors independently abstracted
data on characteristics of patients and interventions, study qual-
ity, endpoints and deviations from protocol using a pre-specified
form designed to complete the information required for the table
of Characteristics of included studies, Table 2 and Table 3. Dif-
ferences were reconciled by discussion or by consultation with a
third review author.
Table 2. Internal Validity
Characteristic Brem 1995 Vuorinen 1997 Westphal 2003 & 2006
Power calculation? No Yes (but inadequate recruitment) Yes
Proper randomisation? Yes Unclear Unclear
Groups similar at baseline? Yes No No
Blinding? Yes Yes Yes
Eligibility criteria stated? Yes Yes Yes
Objecive outcome measures? Some Some Some
Analysis on ITT basis? Yes Yes Yes
All patients accounted for No Yes Yes
Withdrawals specified? No Yes Yes (but not from which arm)
Withdrawal reasons given? No Yes Yes
Conflict of interest? Yes ? Yes
Table 3. External Validity
Criteria Westphal 2003 & 2006 Valtonen 1997 Brem 1995
Age (mean and range) Gliadel: 52.6 (21-72). Placebo:
53.6 (30-67)
Gliadel: 55.5 (36-67). Placebo: 53
(36-65).
Gliadel: 48.1 (SD 12.3). Placebo:
47.6 (SD 13.6)
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Table 3. External Validity (Continued)
Sex (M:F) Gliadel 63:37. Placebo 70:30. Gliadel 50:50. Placebo 63:38. Gliadel 67:33. Placebo 62:38
Histology Gliadel: 84% Grade IV, 16%
Grade III. Placebo: 88%Grade IV,
12% Grade III.
Gliadel: 69% Grade IV, 31%
Grade III. Placebo: 100% Grade
IV, 0% Grade III.
Gliadel: 65.5% Grade IV, 17.2%
Grade III, 17.2% Other. Placebo:
65.2% Grade IV, 18.8% Grade
III, 16.3% Other
KPS (mean and range) Gliadel: 80 (60-100). Placebo: 90
(60-100)
Gliadel: 75 (60-100). Placebo: 90
(40-100).
Gliadel 77 (SD13.1). Placebo:
74.6 (SD12.1)
Extent of Surgery total resection: Gliadel 47% vs
Placebo 41%; partial resection
Gliadel 53% vs Placebo 55%;
lobectomy Gliadel 2% vs Placebo
3%.Mean % of tumour resection:
Gliadel 89.9% vs Placebo 88.3%.
total resection: Gliadel 6% vs
Placebo 6%. Partial: Gliadel 88%
vs Placebo 94%. Lobectomy: Gli-
adel 6% vs Placebo 0%.
Gliadel: 79.9% >75% resection.
Placebo: 78% >75% resection.
Follow up Up to 56 months Greater than 24 months Up to 200 weeks
• For time to event data (survival and time to progression) we
abstracted the HR and its variance from trial reports; if these
were not presented, we attempted to abstract the data required to
estimate them (Parmar 1998). If it was not possible to estimate
the hazard ratio, we planned to abstract the number of patients
in each treatment arm who experienced the outcome of interest
and the number of participants assessed, in order to estimate a
relative risk.
• For dichotomous outcomes (e.g. adverse events) we
abstracted the number of patients in each treatment arm who
experienced the outcome of interest, in order to estimate a
relative risk. For continuous outcomes (e.g. QOL) the final value
and standard deviation of the outcome of interest in each
treatment arm at the end of follow-up was abstracted for each
study. For dichotomous and continuous data, we abstracted the
number of patients assessed at endpoint.
• For continuous outcomes (e.g. QOL) the final value and
standard deviation of the outcome of interest in each treatment
arm at the end of the follow-up was abstracted for each study.
For dichotomous and continuous data, we abstracted the
number of patients assessed at endpoint.
Where possible, all data abstracted were those relevant to an in-
tention to treat (ITT) analysis.
In the case of missing data required for the review outcomes, the
study authors were contacted.
Data extraction was performed by two review authors and inte-
gration to RevMan by a single review author.
Assessment of risk of bias in included studies
Appraisal
Any trial deemed relevant was critically appraised using and were
allocated to one of three groups, described in Section 6 of the
Cochrane Handbook (Higgins 2006) , according to the risk of
bias:
Group A - Low risk of bias
Group B - Moderate risk of bias
Group C - High risk of bias
Trials meeting the quality criteria for group A only were included.
Methodological quality of the included trials
Randomisation:
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• adequate e.g. a computer-generated random sequence or a
table of random numbers (A
• inadequate e.g. date of birth, clinic ID number or surname
(B)
• unclear e.g. not reported (C)
Allocation concealment
• adequate e.g. where allocation concealments could not be
foretold (A)
• unclear e.g. not reported (B)
• inadequate e.g. the computer generated allocation sequence
was displayed so treatment providers could see which arm of the
trial the next participant was assigned to, or kept in a sealed
opaque envelope (C)
• not used (D)
Blinding of participants, treatment providers and outcome
assessors:
• Yes
• No
• Unclear
Loss to follow-up: the number of participants lost to follow up in
each intervention arms whose outcomes were not reported at the
end of the study was recorded; we also noted if loss to follow-up
was not reported.
Any trials meeting the inclusion criteria were critically appraised
with tables constructed to summarise internal and external validity
(Juni 2001).
Data synthesis
We pooled the results of trials of primary therapy and therapy for
recurrent disease in separate meta-analyses.
• For time to event data, HRs were pooled using the generic
inverse variance facility of RevMan 4.2.
• For dichotomous outcomes calculated the relative risk (RR)
for each study and then pooled the RRs.
• For continuous outcomes we pooled the weighted mean
differences between the treatment arms at the end of follow-up
using the mean difference method if all trials have measured the
outcome on the same scale, or using the standardised mean
difference method otherwise.
Fixed effects models were used for all meta-analyses.
In light of the known benefits of chemotherapy in primary disease,
we planned to assign trials including systemic chemotherapy in
the control arm to a separate sub-roup and pool results of sub-
groups if they showed consistent findings.
If sufficient studies were available, we planned to construct a fun-
nel plot of treatment effect versus precision with the data from all
studies included in order to investigate the likelihood of publica-
tion bias.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The search strategy identified 121 potentially relevant references
which were screened online. We excluded 112 references and re-
trieved 9 for detailed evaluation.
Included studies
The three included studies are described in detail in the table of
Characteristics of Included Studies
Primary therapy
Two studies (reported by three articles) met the inclusion criteria.
The first trial was set in four Scandinavian neurosurgical hospitals
(Valtonen 1997). It included patients (entry criteria aged 18 to 65)
who had a good Karnofsky Performance Score (KPS) at baseline
(KPS 60 of more). It studied Gliadel wafers or identical placebo
wafers not coated in carmustine implanted after resection when
GBM was confirmed on frozen section. Further management in
both arms included radiotherapy but not systemic chemotherapy.
The trial was blinded to participants, treatment providers and out-
come assessors. Therapy for recurrence was not specified in ad-
vance. The primary outcome was survival; secondary outcomes
included adverse events and mortality. It was terminated prema-
turely due to difficulty in sourcing new wafers.
The second and largest trial recruited patients from multiple cen-
tres through Europe (Westphal 2003). The remaining study crite-
ria were almost identical to those of the earlier trial. Further sec-
ondary outcome measures included PFS, time to neuro perfor-
mance measure decline, and median time to decline of Karnofsky
performance score (defined as a change of 10 or more in KPS). A
follow up paper presented long term data relating to survival using
alternative statistical methods (Westphal 2006).
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Therapy for recurrence
A single trial met the inclusion criteria (Brem 1997). It was set in
27 Neurosurgical centres in the USA and Canada. It included all
people who had previously confirmed HGG treated with surgery
and radiotherapy. Recurrence was defined on radiological criteria
alone. The interventions were maximal resection followed by im-
plantation ofGliadel wafer or identical placebowafer not coated in
carmustine. All participants, treatment providers and outcome as-
sessors were blinded to study group. As the maximal dose of radia-
tion was given no further radiotherapy was available as a treatment
option. Following intervention subsequent treatment including
chemotherapy was given as required and not according to a pre-
defined protocol. The primary outcome was survival; secondary
outcome measures included adverse events and mortality.
Excluded studies
We excluded six references for the following reasons:
• A meta-analysis of Gliadel for primary therapy (Mulrow
2003);
• A web based publication for a university technology
assessment unit (Brophy 2004);
• Two phase III studies of wafers other than Gliadel that did
not clearly meet our inclusion criteria (Dalbasti 2002; Sheleg
2002);
• A phase II study of Gliadel (Brem 1995).
• A retrospective series of the results of Gliadel use in a single
institution (Kleinberg 2004).
Risk of bias in included studies
A full analysis of the internal validity of the included studies is
presented in Table 2 and summarised below.
Primary gliadel therapy
The design characteristics and internal validity of both trials were
similar. Methods of randomisation were not fully described but
inclusion/exclusion criteria were and the groups were similar at
baseline. Good attention was given to conceal treatment allocation
and blind all those involved to treatment groups. The dummy
placebo wafer was designed to be identical to Gliadel. Eligibility
and ineligibility criteria were clear. Analysis was on an ITT basis,
with all patients accounted for and all withdrawals specified. There
were no significant methodological differences between the trials
to prevent pooling their results in meta-analysis. Therefore both
included trials were deemed to be at low risk of bias and eligible
for inclusion.
In the trials Westphal 2003 andWestphal 2006 the outcome mea-
sures of PFS andQOL used were subjective. The use of time to de-
cline in Karnofsky Performance Status as a marker of progression
is not an accurate indicator of progression, as many other factors
other than recurrence can affect KPS, hence this was not included
in the results. The use of time to decline in neuro performance
indicators was not specified as a valid measure of progression or
QOL and hence was also not included in the final analysis. The
choice of stratification by country in the statistical methods of the
original article was incorrect, although this was amended in the
later article. Survival data is taken from the later trial only in light
of this.
The trial byWestphal 2003 also included a difference in the num-
ber of Grade III tumours in each arm (13 in the Gliadel arm
and 8 in the Placebo arm). Final analysis of histological subtype
was performed after randomisation and application of treatment
meaning it would not have been possible for this discrepancy to
affect the arm a participant was assigned to i.e. there was no risk
of allocation bias. Discrepancy of this kind in the baseline char-
acteristics of treatment groups should be minimised by combina-
tion in meta-analysis. The lead pathologists were also blinded to
treatment group preventing bias is subsequent treatment.
Adverse events in all the included studies contained serious
methodological flaws. The trial by Valtonen 1997 chose to report
adverse event rates descriptively rather than in tables. The article
by Westphal 2003 did provide a table of individual nervous sys-
tem adverse events (occurring in grater than 5% of participants)
for each arm but not for total events. There was no attempt to
discuss the severity of events and the number of patients who had
multiple episodes i.e. only total numbers of events were specified
rather than the risk for each patient. Therefore it is not possible to
provide a detailed description of adverse events according to our
specified outcome criteria.
Gliadel for recurrence
Methods of randomisation were not described fully. Good atten-
tion was given to blind all those involved in treatment group. The
placebo wafer used was identical to Gliadel and this would not
have been able to reveal the treatment group a patient was in.
Recurrence was defined on radiological criteria alone rather than
using more accurate clinical and radiological criteria (MacDonald
1990). There is doubt therefore as to whether all patients had true
recurrent disease or merely changes on imaging that could be con-
fused with radiation necrosis. Analysis was stated to be on an ITT
basis but not all patients or withdrawals were specified. There was
incomplete reporting of results regarding QOL data which meant
the data was not presented in the article. Adverse events were pre-
sented in a descriptive fashion rather than in tables. It was not
clear what the overall adverse event rates were or if single patients
suffered multiple events.
Effects of interventions
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Primary therapy
Gliadel® resulted in an increase in survival comparedwith placebo
(HR 0.65, CI 0.48 to 0.86, p = 0.003). Fixed effects models were
used as the entry criteria for each study were broadly inclusive.
As only two trials were included and both demonstrated a sur-
vival benefit individually it was apparent that there was no gross
heterogeneity between the trials and a formal statistical test of
heterogeneity was deemed unnecessary. No data was included for
time to progression or QOL. Adverse events are presented in a
descriptive manner due to the low number of events. No study
reported any peri-operative mortality. The results for specific ad-
verse events were not statistically more common between arms
within each study. Adverse event rates included total event rates of
12/16 (75%) of Gliadel patients and 9/16 (56%) of placebo pa-
tients (non-significant) (Valtonen 1997). The rates of neurological
complications were not more common in either arm (Westphal
2003).
Therapy for recurrence
Gliadel® did not confer any survival benefit over placebo (HR
0.83, CI 0.62 to 1.10, p = 0.2). There was no data available from
the trials to calculate time to progression of QOL. Adverse events
included no peri-operative mortality in either arm. There was no
statistically significant difference in the rates of the rates of indi-
vidually specified adverse events. There were 5 cases of infection
(Gliadel 4, Placebo 1) and 73 cases of seizures (Gliadel 41, Placebo
32).
As only three studies were included we did not construct a funnel
plot.
D I S C U S S I O N
The study indicates a survival benefit for the use of Gliadel® and
radiotherapy compared to radiotherapy alone as part of primary
therapy in highly selected patients. Although the HR remains the
most appropriate statistic to present survival data, clinicians are
often more familiar with median survivals and survival percent-
ages at fixed time points. Overall Gliadel® resulted in a 35% risk
reduction for death. The trials suggest a median survival with Gli-
adel® of around 14 months with a 2.5 month improvement over
placebo. Survival is around 10% better with Gliadel® at 1 and 2
years, although analysis of the survival curves from the individual
trials suggests that the increase in survival occurs mainly after one
year. These figures are similar to those seen in the meta-analysis
of PCV chemotherapy (Stewart 2002) and the largest RCT with
temozolomide (Stupp 2005).
There is not a demonstrable survival benefit for the use of Gli-
adel® in recurrent disease. Analysis of the survival curve in the
included study suggests no difference between arms. Survival after
recurrence is usually short, with amedian of around sixmonths. At
recurrence GBM may have developed a resistance to chemother-
apy by this point, making even topical application of carmustine
ineffective. Local factors such as radiotherapy induced changes
and gliosis may limit the diffusion of chemotherapy around the
resection margin in recurrent disease.
Data presentation for secondary outcomes was poor in the in-
cluded studies, hindering meta-analysis. Time to progression was
hindered by a large duration between assessments reducing the
sensitivity to a level which may result in missing a difference that
was really there. The criteria used for determining progression
should have included clinical as well as radiological criteria to im-
prove accuracy. Collection of QOL data was poor and lead to the
discontinuation of this trial outcome in the largest study. Adverse
event rates of Gliadel® were not significantly higher than placebo
wafers, although the total number of patients suffering adverse
events were incompletely reported in the largest trial. It is not clear
whether a wafer itself confers a risk of adverse events above that
of standard resection, although an initial phase 1 trials suggested
it was well tolerated (Brem 1995).
The inclusion of Grade III tumours in the Gliadel arm, which
are a subgroup known to have a better survival than GBM. This
inequality was noted when pathology was re-examined at a cen-
tral location, although not all tumours were submitted and final
grading was made by a single pathologist. Grade III tumours are
known to have a longer survival and increased response to che-
motherapy compared with Grade IV tumours, although there is
no reliable proof that chemotherapy increases survival in Grade
III tumours (Siker 2006). Histological grading is known to differ
between pathologists (Castillo 2004), but as allocation conceal-
ment was well maintained it is unlikely that any deliberate bias
could have arisen. For practical purposes the methods of the trial
are robust and from an ITT perspective the results are sound.
The management for recurrence was aggressive with up to 30%
undergoing surgery for recurrence. After primary therapy, themax-
imal dose of radiotherapy tolerated has already been given, leav-
ing surgery or chemotherapy as the main management options.
Chemotherapy is usually preferred in light of the poor prognosis,
leaving surgery for those with clear indications such as an easily
accessible lesion, obstructive hydrocephalus or raised intra-cranial
pressure. Bias at this stage is still unlikely given that management
was blinded and there was no difference in survival after recurrence
between the arms.
The generalisability of the patients and interventions used in the
two included studies is summarised inTable 3. All studies recruited
patients under 65 years old with a good performance score. This
limits the applicability of results to the GBM population as a
whole. In addition, only patients with GBMwere studied and not
those with other forms of HGG. A study of recruitment in one
of the trial centres estimated that around 30% of those presenting
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would be suitable for consideration of primary Gliadel® therapy
(Whittle 2003).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is evidence that Gliadel® increases survival in primary ther-
apy for GBM but not for recurrent disease, and that this benefit
is without a significant increase in adverse events. There is no ev-
idence of enhanced PFS or QOL. These findings are based pre-
dominantly on two well designed trials with a total of just under
300 patients. In a well selected subgroup of patients presenting
with presumed GBM, Gliadel® warrants consideration for use
as primary therapy. Decisions on the use of Gliadel® need to be
made on an individual basis as part of a multi-disciplinary team
discussion.
Implications for research
Further studies focusing on molecular markers to predict tumour
response are needed to better identify those patients who will ben-
efit from Gliadel® (Kim 2006). There is also scope to examine
the role of Gliadel® in combination with other therapies, as there
is likely to be a synergistic effect due to the multiple pathways
involved in tumourogenesis. In all future trials better attention
needs to be paid to secondary outcome measures, and entry cri-
teria should be expanded to include a broader range of patients
with other forms of HGG. A trial comparing Gliadel with temo-
zolomide is warranted in light of the similar survival benefits in
the same patient population.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Brem 1997
Methods RCT
Participants 222 consecutive patients from 27 centres in the USA and Canada (1/3/89-17/1/92).
Eligibility criteria: presence of a single unilateral single focus of tumour in the cerebrum showing at least
1.0cm3 enhancing volume on CT or MRI; KPS 60 or more; completion of external beam radiation
therapy; and no nitrosureas for 6 weeks and no other systemic chemotherapeutic agent for 4 weeks before
enrollement. In addition, patients’ surgeons made an independent determination that another tumour
resection would be done irrespective of the study.
Ineligibility criteria; not stated
Interventions Up to eight discs of Gliadel or identical placebo wafer applied to the resection cavity. Post-operative radio-
therapy was administered to both arms according to protocol. Further treatment was given as neccessary.
Outcomes Primary: Survival
Secondary: rates of complications, toxicity, quality of life.
Notes All patients: median survival 31 versus 23 weeks; HR 0.83 CI 0.63-1.10 p=0.19
All patients survival at 6 months: 53% versus 40%, p=0.061
All patients Cox model: HR 0.67 CI 0.51-0.9 p=0.006
GBM subgroup analysis: HR 0.81 p=0.22
GBM subgroup Cox model: HR 0.67 CI 0.48-0.95 p=0.02
Adverse events: no peri-operative mortality. Intra-cranial infection cases: 4 (Gliadel) versus 1 (Placebo).
Seizure cases: 41 (Gliadel) versus 32 (Placebo).
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Valtonen 1997
Methods RCT
Participants 32 consecutive patients from 4 Scandinavian University hospital neurosurgery units (03/1992-03/1993).
Inclusion criteria: age 18-65 years; Grade III or IV tumour; KPS of 60 or more, and; unilateral, unifocal
tumour of at least 1 cm in diameter.
Exclusion criteria: significant renal, hepatic or haematological dysfunction; other concomitant life threat-
ening disease; pregnancy; hypersensitivity to radiographic contrast media, and; evidence of systemic dis-
ease.
Interventions Intra-operative placement of 8 or fewer Gliadel or identical placebo wafers (i.e. 61.6mg or less of BCNU).
Radiotherapy: ’standard’ RT (not detailed) was given to both arms post-operatively. Further management
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Valtonen 1997 (Continued)
was provided according to need.
Outcomes Primary: Survival.
Secondary: 2 year survival.
Notes Median survival: Gliadel 58.1 (42-undetermined)versus Placebo 39.9 (37.6-45) weeks
Cox model for time from surgery to death for all patients; HR 0.27, CI 0.11-0.68, p=0.006
Subgroup analysis for survival of GBM only patients
Cox model for time from surgery to death for GBM only patients; HR 0.27, CI 0.10-0.71, p=0.008
Adverse events: no peri-operative mortality. 21 complications (Gliadel 12, Placebo 9).
No quality of life or time to progression data
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Westphal 2003
Methods RCT
Participants 240 consecutive patients from 38 centres in 14 countries (12/1997-07/1999).
Inclusion criteria were: age 18-65 years; Grade III or IV tumour; KPS of 60 or more; single, contrast
enhancing unilateral supratentorial tumour, and; surgery within 2 weeks of baseline MRI.
Exclusion criteria were: prior cytoreductive therapy; prior radiotherapy to the brain; known hypersensi-
tivity to nitrosureas, and; ’clinically significant laboratory abnormalities.’
Interventions Intra-operative placement of 8 or fewer Gliadel or identical placebo wafers (i.e. 61.6mg or less of BCNU).
Radiotherapy: 55-60Gy in 30-33 daily fractions 5 days a week to a focal area with a 2-5 cm margin for
both arms. Further management was provided according to need.
Outcomes Primary: Survival.
Secondary: Time to KPS decline: Time to Neurological Progression; PFS: QoL: Adverse events.
Notes Median surival: Gliadel 13.9 versus Placebo 11.6 months; HR 0.71 CI 0.52-0.96 p=0.03 (stratified by
country)
1 year survival: Gliadel 59.2 versus Placebo 49.6%
Cox model for survival in all patients
Kaplan-Meier censoring for re-operation; median survival Gliadel 14.6 versus Placebo 11.4, HR 0.64, CI
0.45-0.92, p=0.01
GBM only subgroup analysis; median survival Gliadel 13.5 versus Placebo 11.4, HR 0.76, CI 0.55-1.05,
p=0.01
Cox model for GBM subgroup; HR 0.69, CI 0.03-0.51, p=0.04
KPSmedian time to decline: Gliadel 11.9 versus Placebo 10.4. Deterioration at 1 year: Gliadel 47.5 versus
Placebo 39.3
Neuroperformance measures decline: longer time for all measures with Gliadel
PFS: 5.9 months both arms, p=0.9
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Westphal 2003 (Continued)
Adverse events: no peri-operative mortality. Detailed table of neurological adverse events occurring with
a frequency of greater than 5%
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Westphal 2006
Methods RCT
Participants As Westphal 2003
Interventions As Westphal 2003
Outcomes As Westphal 2003
Notes All patients: Median survival Gliadel 13.8 versus Placebo 11.6 months; HR 0.73 CI 0.56-0.95 p=0.018
Survival at 1 year: Gliadel 59% versus Placebo 49%; 2 years: 16% versus 8%; 3 years: 9% versus 2%
Cox model for all patients HR 0.75 CI 0.57-0.99 p=0.045
GBM subgroup analysis: median survival Gliadel 13.1 versus Placebo 11.4 months, HR 0.78 CI 0.60-
1.03 p=0.08
Cox model for GBM subgroup: HR 0.78 CI 0.58-1.05 p=0.1
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
RCT = Randomised Controlled Trial; KPS = Karnofsky Performance Score; PFS = Progression Free Survival; QoL = Quality of Life.
Characteristics of excluded studies [ordered by study ID]
Brem 1995 This is a prospective phase I trial aimed at assessing the safety of Gliadel wafers as a precept to a full RCT (Westphal
2003). It examined 22 patients in 3 US centres between 07/1990 and 08/1991. The trial was complete when a
single centre had randomised 10 patients. Primary outcomes were complications and functional status, secondary
outcomes were survival.
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(Continued)
Brophy 2004 This is a web based publication assessing Gliadel for primary therapy in HGG. It is undertaken by a University to
assess efficacy and costs in a specific region. No meta-analysis is presented.
Dalbasti 2002 40 patients with previous de novo GBM and recurrent disease between January 1997 and December 1999. KPS
of 70% or higher. Randomised into control, systemic fotemustine, bucladesine wafers, or bucladesine wafers with
fotemustine.
Kleinberg 2004 Case series.
This is a retrospective case series of the experience of Gliadel wafers in a single US University hospital oncology
centre. It examined 45 patients between 07/1990 and 08/1999. Primary outcome was surgical outcome, secondary
outcomes were survival, toxicity, steroid dosing and histopathological findings at re-operation.
Mulrow 2003 This is a meta-analysis of Gliadel therapy presented as Confernce Proceedings. No formal search strategy or
systematic review was undertaken.
Sheleg 2002 38 patients with between January 1998 and January 2000.
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D A T A A N D A N A L Y S E S
Comparison 1. Primary Gliadel Therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Survival 2 HR and variance (Random, 95% CI) 0.49 [0.19, 1.23]
Comparison 2. Gliadel for Recurrence
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Survival 1 HR and variance (Fixed, 95% CI) 0.83 [0.62, 1.10]
Analysis 1.1. Comparison 1 Primary Gliadel Therapy, Outcome 1 Survival.
Review: Chemotherapeutic wafers for High Grade Glioma
Comparison: 1 Primary Gliadel Therapy
Outcome: 1 Survival
Study or subgroup log [HR and variance] HR and variance Weight HR and variance
(SE) IV,Random,95% CI IV,Random,95% CI
Valtonen 1997 -1.309 (0.4742) 39.3 % 0.27 [ 0.11, 0.68 ]
Westphal 2006 -0.3425 (0.1565) 60.7 % 0.71 [ 0.52, 0.96 ]
Total (95% CI) 100.0 % 0.49 [ 0.19, 1.23 ]
Heterogeneity: Tau2 = 0.34; Chi2 = 3.75, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 1.53 (P = 0.13)
0.1 0.2 0.5 1 2 5 10
Favours Gliadel Favours Placebo
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Analysis 2.1. Comparison 2 Gliadel for Recurrence, Outcome 1 Survival.
Review: Chemotherapeutic wafers for High Grade Glioma
Comparison: 2 Gliadel for Recurrence
Outcome: 1 Survival
Study or subgroup log [HR and variance] HR and variance Weight HR and variance
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Brem 1997 -0.1863 (0.145) 100.0 % 0.83 [ 0.62, 1.10 ]
Total (95% CI) 100.0 % 0.83 [ 0.62, 1.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
0.1 0.2 0.5 1 2 5 10
Favours Gliadel Favours Placebo
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